EuroBiotech—More articles of note


> Atox Bio raised $30 million. The financing equips the Israeli biotech to complete a phase 2 trial in acute kidney injury and a phase 3 study in necrotizing soft tissue infections. Data from both trials are expected in 2019. Statement

> BioInvent and Transgene agreed to collaborate on an anti-CTLA-4 antibody to treat solid tumors. Release

> Scotland’s TC BioPharma struck a CAR-T deal with Bluebird Bio. Bluebird is paying $16 million upfront to work with the startup. The collaborators’ goals include the advancement of TC’s lead CAR-engineered gamma delta T cell program into human testing. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Advicenne raised €27 million in a Paris IPO. Release

> GenSight Biologics posted long-term data on its gene therapy treatment for Leber hereditary optic neuropathy. Statement (PDF)

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.